Industry
AimedBio secures tech transfer and establishes foothold on KOSDAQ, backed by government drug development support
South Korea\'s Ministry of Science and ICT said on Wednesday that AimedBio, which grew with step-by-step government support for new drug development, has established itself in the KOSDAQ market as a successful case of commercialising public research. The company developed next-generation targeted cancer drugs using antibody-drug conjugate technology. It signed a technology transfer contract worth about 1.4 trillion won and recorded a market capitalisation of about 2.8 trillion won on its KOSDAQ listing day.
